Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Low Level Laser Therapy Versus Pharmacotherapy in in Improving Masticatory Muscle Pain

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2012 by saranaz azari-marhabi, Shahid Beheshti University.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
saranaz azari-marhabi, Shahid Beheshti University Identifier:
First received: August 4, 2012
Last updated: August 6, 2012
Last verified: August 2012
tempromandibuar disorders are a group of heterogenous pathologies affecting temporomandibular joint,muscles or more than 90%of cases muscles are the origin of pain.TMDs cause pain,movement disability and deficit in quality of more than 90%of cases pain is the major complaint.we run this investigation to find the analgesic effct of low level laser therapy versus pharmacotherapy with naproxen in improving pain.

Condition Intervention Phase
Radiation: low level laser therapy
Drug: Naproxen
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase 1 Study of Low Level Laser Therapy Versus Naproxen

Resource links provided by NLM:

Further study details as provided by saranaz azari-marhabi, Shahid Beheshti University:

Primary Outcome Measures:
  • reduction of paim measured by VAS [ Time Frame: 1 month ]
    VAS is visual analogue scale

Estimated Enrollment: 40
Study Start Date: June 2012
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low level laser therapy
this arm recieves low level laser therapy treatment for 12 sessions.
Radiation: low level laser therapy
Experimental: naproxen
this arm takes naproxen 500 mg twice daily for 3weeks
Drug: Naproxen


Ages Eligible for Study:   15 Years to 65 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • patients with TMD affecting masticatory muscles

Exclusion Criteria:

  • systemic disease
  • GI problem
  • pregnancy
  • epidermal cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01659372

Contact: saranaz azari marhabi, post graduate student 00989190129151

Iran, Islamic Republic of
Shahid Beheshti University Not yet recruiting
Tehran, Iran, Islamic Republic of, 1983969411
Shahid Beheshti University Recruiting
Tehran, Iran, Islamic Republic of, 1983969411
Contact: saranaz azari-marhabi, doctor    00989190129151   
Principal Investigator: saranaz azari-marhabi, resident         
Sponsors and Collaborators
Shahid Beheshti University
  More Information

Responsible Party: saranaz azari-marhabi, oral medicine resident, Shahid Beheshti University Identifier: NCT01659372     History of Changes
Other Study ID Numbers: ABT-1233-RV
Study First Received: August 4, 2012
Last Updated: August 6, 2012

Keywords provided by saranaz azari-marhabi, Shahid Beheshti University:
temporomandibular disorder
myofascial pain syndrome

Additional relevant MeSH terms:
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gout Suppressants
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017